慢性阻塞性肺疾病急性加重期表型的最新进展。
The recent advances of phenotypes in acute exacerbations of COPD.
作者信息
Zhou Aiyuan, Zhou Zijing, Zhao Yiyang, Chen Ping
机构信息
Department of Respiratory Medicine, The Second Xiangya Hospital; Research Unit of Respiratory Disease; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, People's Republic of China.
出版信息
Int J Chron Obstruct Pulmon Dis. 2017 Mar 27;12:1009-1018. doi: 10.2147/COPD.S128604. eCollection 2017.
Abstract
Exacerbations of COPD are clinically relevant events with therapeutic and prognostic implications. Yet, significant heterogeneity of clinical presentation and disease progression exists within acute exacerbations of COPD (AECOPD). Currently, different phenotypes have been widely used to describe the characteristics among patients with AECOPD. This has proved to be significant in the treatment and prediction of the outcomes of the disease. In this review of published literature, the phenotypes of AECOPD were classified according to etiology, inflammatory biomarkers, clinical manifestation, comorbidity, the frequency of exacerbations, and so on. This review concentrates on advancements in the use of phenotypes of AECOPD.
摘要
慢性阻塞性肺疾病（COPD）急性加重是具有治疗和预后意义的临床相关事件。然而，COPD急性加重（AECOPD）患者的临床表现和疾病进展存在显著异质性。目前，不同的表型已被广泛用于描述AECOPD患者的特征。这在该疾病的治疗和结局预测中已被证明具有重要意义。在这篇已发表文献的综述中，AECOPD的表型根据病因、炎症生物标志物、临床表现、合并症、加重频率等进行了分类。本综述重点关注AECOPD表型应用方面的进展。
相似文献
1
The recent advances of phenotypes in acute exacerbations of COPD.
Int J Chron Obstruct Pulmon Dis. 2017 Mar 27;12:1009-1018. doi: 10.2147/COPD.S128604. eCollection 2017.
2
Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Int J Chron Obstruct Pulmon Dis. 2015 Oct 28;10:2319-25. doi: 10.2147/COPD.S87091. eCollection 2015.
3
Serum Endostatin Is a Novel Marker for COPD Associated with Lower Lung Function, Exacerbation and Systemic Inflammation.
Int J Chron Obstruct Pulmon Dis. 2020 Feb 25;15:397-407. doi: 10.2147/COPD.S234760. eCollection 2020.
4
Acute exacerbation of COPD: is it the "stroke of the lungs"?
Int J Chron Obstruct Pulmon Dis. 2016 Jul 13;11:1579-86. doi: 10.2147/COPD.S106160. eCollection 2016.
5
Inflammation and infections in unreported chronic obstructive pulmonary disease exacerbations.
Int J Chron Obstruct Pulmon Dis. 2019 Apr 10;14:823-832. doi: 10.2147/COPD.S191946. eCollection 2019.
6
Recovery Following Acute Exacerbations of Chronic Obstructive Pulmonary Disease - A Review.
COPD. 2019 Feb;16(1):93-103. doi: 10.1080/15412555.2019.1598965. Epub 2019 May 2.
7
Exacerbations of COPD.
Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss(Spec Iss):21-30. doi: 10.2147/COPD.S85978. eCollection 2016.
8
Acute exacerbations of COPD: risk factors for failure and relapse.
Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687-2693. doi: 10.2147/COPD.S145253. eCollection 2017.
9
Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation.
J Proteomics. 2012 Jun 6;75(10):2835-43. doi: 10.1016/j.jprot.2012.01.027. Epub 2012 Feb 10.
10
The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia.
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2469-78. doi: 10.2147/COPD.S90330. eCollection 2015.
引用本文的文献
1
Phenotypes of Exacerbations in Chronic Obstructive Pulmonary Disease.
J Clin Med. 2025 Apr 30;14(9):3132. doi: 10.3390/jcm14093132.
2
Effects of pulmonary rehabilitation on systemic inflammation in chronic obstructive pulmonary disease: a meta-analysis.
Am J Clin Exp Immunol. 2024 Feb 25;13(1):1-11. doi: 10.62347/ZHGD4216. eCollection 2024.
3
Stepwise management of COPD: What is next after bronchodilation?
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208630. doi: 10.1177/17534666231208630.
4
Effectiveness and safety of Suhuang Zhike capsule as adjuvant treatment for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis.
J Tradit Chin Med. 2023 Apr;43(2):231-238. doi: 10.19852/j.cnki.jtcm.2023.02.004.
5
Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD.
PLoS One. 2022 Dec 8;17(12):e0277357. doi: 10.1371/journal.pone.0277357. eCollection 2022.
6
Impact of Acute Exacerbation and Its Phenotypes on the Clinical Outcomes of Chronic Obstructive Pulmonary Disease in Hospitalized Patients: A Cross-Sectional Study.
Toxics. 2022 Nov 6;10(11):667. doi: 10.3390/toxics10110667.
7
Giving Voice to People - Experiences During Mild to Moderate Acute Exacerbations of COPD.
Chronic Obstr Pulm Dis. 2022 Jul 29;9(3):336-348. doi: 10.15326/jcopdf.2022.0283.
8
Comparison of peak expiratory Flow(PEF) and COPD assessment test (CAT) to assess COPD exacerbation requiring hospitalization: A prospective observational study.
Chron Respir Dis. 2022 Jan-Dec;19:14799731221081859. doi: 10.1177/14799731221081859.
9
Phenotyping acute exacerbation of COPD: what more can we do for hospitalised patients?
ERJ Open Res. 2021 Aug 2;7(3). doi: 10.1183/23120541.00362-2021. eCollection 2021 Jul.
10
Association of serum vitamin D levels with disease severity, systemic inflammation, prior lung function loss and exacerbations in a cohort of patients with chronic obstructive pulmonary disease (COPD).
J Thorac Dis. 2021 Jun;13(6):3597-3609. doi: 10.21037/jtd-20-3221.
本文引用的文献
1
Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: Implications and Future Research.
Chin Med J (Engl). 2016 Sep 5;129(17):2017-9. doi: 10.4103/0366-6999.189071.
2
Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD.
Int J Chron Obstruct Pulmon Dis. 2016 Jun 22;11:1381-9. doi: 10.2147/COPD.S104051. eCollection 2016.
3
Meta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease.
Clin Respir J. 2018 Jan;12(1):10-15. doi: 10.1111/crj.12519. Epub 2016 Jul 8.
4
Role of Eosinophil Granulocytes in Allergic Airway Inflammation Endotypes.
Scand J Immunol. 2016 Aug;84(2):75-85. doi: 10.1111/sji.12448.
5
The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease.
Qatar Med J. 2016 Jan 26;2015(2):18. doi: 10.5339/qmj.2015.18. eCollection 2015.
6
Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD Assessment Test.
Int J Chron Obstruct Pulmon Dis. 2015 Oct 20;10:2257-63. doi: 10.2147/COPD.S92160. eCollection 2015.
7
Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal.
Lancet Respir Med. 2015 Sep;3(9):729-734. doi: 10.1016/S2213-2600(15)00242-8. Epub 2015 Jul 9.
8
[Effect of Qi Benefiting Blood Activating Method on Plasma Fibrinogen and D-dimer in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 May;35(5):537-40.
9
Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease.
Ann Am Thorac Soc. 2015 Jul;12(7):997-1004. doi: 10.1513/AnnalsATS.201408-359OC.
10
Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD.
Wien Klin Wochenschr. 2015 Oct;127(19-20):756-63. doi: 10.1007/s00508-014-0690-6. Epub 2015 Jan 14.
Zotero 插件